THE WIRE · № 85478
Masimo's smartSET™ FDA Clearance Offers Breakthrough Innovation in Pulse Oximetry to Help Improve Critical Patient Outcomes
01 THE MACHINE READ
WHY IT MATTERS.
FDA clearance expands Masimo's pulse-oximetry feature set, a product-level catalyst that could support share of hospital monitoring budgets.
Regulatory win adds a product catalyst
Hospital adoption and reimbursement decisions
Adoption slower than marketing implies
FULL DISPATCH
Industry-Leading Pulse Oximetry Platform Now Features First-of-Its-Kind Atrial Fibrillation (AFib) Detection with Previously Cleared AI-Enabled Opioid-Induced Respiratory Depression (OIRD) Detection Designed Together to Deliver Earlier Clinical Insights IRVINE, Calif., Oct. 17, 2026...
02 THE STORY SO FAR
THE RECORD, IN ORDER.
STANDALONE ITEM — NOT YET FOLDED INTO A DEVELOPING STORY.
03 WHO'S INVOLVED
ENTITIES ON FILE.
04 RECEIPTS
THE SOURCE RECORD.
1 SOURCES CONFIRMED05 PROPAGATION
WHAT THIS TOUCHES.
VeraDermics raises $472M in post-IPO equity after hair-loss drug IPO soars 567%2026-10-17 13:30 UTC
Viatris Receives U.S. FDA Approval for RYZUMVI® for the Treatment of Presbyopia2026-10-16 20:05 UTC
Eli Lilly buys about $12.3M in TRex Bio (TRXB) IPO shares, adding to its holdings.2026-10-16 20:19 UTC
AMCP Market Insights Findings Show Uncertainty in Biomarker Testing for ESR1-Mutated Advanced Breast Cancer as Payers Weigh Earlier Detection and a Growing Class of Targeted Therapies2026-10-16 21:03 UTC
City Therapeutics' Upsized $200M IPO Joins Biotech Wave2026-10-16 21:56 UTC
Hospital Operator Challenges NC AG's Power Over Merger2026-10-16 23:29 UTC
KEEP READING THE MACHINE
Summaries are generated and may contain errors — every claim links its sources.